Economist Justin Wolfers Points To Obesity Rate Decline As Ozempic And Wegovy Spur Historic Shift In Fight Against Obesity — Has US Reached A Turning Point?
Economist Justin Wolfers Points To Obesity Rate Decline As Ozempic And Wegovy Spur Historic Shift In Fight Against Obesity — Has US Reached A Turning Point?
The potential catalyst for this unprecedented decline? A new generation of diabetes and weight loss drugs, including Ozempic and Wegovy. These medications, which have shown remarkable results in clinical trials, are now being used by a significant portion of the U.S. population. The United States may have reached a turning point in its decades-long battle against obesity. Recent data suggests that 2020 could mark the year when obesity rates in America not only peaked but began to decline, echoing the historic moment in 1963 when cigarette sales in the U.S. hit their apex before falling.
美國可能已經在長達幾十年的與肥胖作鬥爭中達到一個轉折點。最近的數據表明，2020年可能標誌着美國肥胖率不僅達到峯值，而且開始下降，這與1963年美國香菸銷量達到頂峯並開始下降的歷史時刻相呼應。
What Happened: Renowned economist Justin Wolfers highlighted this significant shift on social media platform X, stating, "From the Department of Things Really Are Getting Better: The U.S. obesity rate may have peaked, and for the first time in a long time, it fell last year." Wolfers attributes this change to new weight loss drugs, adding, "Chalk up another one to progress."
發生了什麼：知名經濟學家賈斯汀·沃爾弗斯在社交媒體平台X上強調了這一重大轉變，稱：「從真的在變好的事類別中：美國肥胖率可能已經達到峯值，而且長時間以來，去年首次下降。」 沃爾弗斯將這一變化歸因於新的減肥藥物，並補充道：「再加一分給進步。」
John Burn-Murdoch, writing an opinion piece for the Financial Times, suggests that one in eight U.S. adults have used these drugs, with 6% currently taking them.
約翰·伯恩-默多克在《金融時報》撰寫的一篇觀點文章中指出，美國成年人中有八分之一使用了這些藥物，目前有6%的人正在服用這些藥物。
The potential catalyst for this unprecedented decline? A new generation of diabetes and weight loss drugs, including Ozempic and Wegovy. These medications, which have shown remarkable results in clinical trials, are now being used by a significant portion of the U.S. population.
引發這一史無前例下降的潛在催化劑是什麼？一代新的糖尿病和減肥藥物，包括奧塞康和維戈維。這些藥物在臨床試驗中表現出色，並現在被美國相當一部分人口使用。
As the U.S. leads this potential obesity decline, other countries are likely to follow suit. In Denmark, home to Novo Nordisk (NYSE:NVO), the creator of Ozempic and Wegovy, 3% of adults were using these drugs by the end of 2023, coinciding with a slowdown in obesity rate increases.
隨着美國引領這一潛在的肥胖率下降，其他國家可能也會效仿。在丹麥，奧塞康和維戈維的生產商諾和諾德（紐交所：NVO）位於該國，到2023年底，有3%的成年人在使用這些藥物，與肥胖率增長放緩相一致。
From the Department of Things Really Are Getting Better: The U.S. obesity rate may have peaked, and for the first time in a long time, it fell last year.
— Justin Wolfers (@JustinWolfers) October 5, 2024
And yes, it's the new weight loss drugs, which really work. Chalk up another one to progress. pic.twitter.com/icLjvfR57u
從真的在變好的事類別中：美國肥胖率可能已經達到峯值，而且長時間以來，去年首次下降。
— 賈斯汀·沃爾弗斯（@JustinWolfers）2024年10月5日
而且，沒錯，就是那些真的奏效的新減肥藥物。再加一分給進步。pic.twitter.com/icLjvfR57u
Why It Matters: The decline in obesity rates is significant in the context of recent developments in the pharmaceutical industry. Roche Holdings AG (OTC:RHHBY) has fast-tracked its obesity drug development, aiming for over $3 billion in sales potential. This move underscores the growing market for effective weight loss treatments.
爲什麼重要：肥胖率下降在當前藥品行業發展的背景下具有重要意義。諾華控股（OTC:RHHBY）已加快了其肥胖藥品的研發，旨在實現超過300 億美元的銷售潛力。這一舉動凸顯了適用於有效減重治療的市場需求不斷增長。
Additionally, Eli Lilly and Co (NYSE:LLY) is exploring broader applications for its weight-loss drugs, Mounjaro and Zepbound, targeting individuals with a lower BMI.
此外，禮來（NYSE:LLY）正在探索其減肥藥品Mounjaro和Zepbound的更廣泛應用，針對BMI較低的個體。
Despite the promising results, a recent study reveals a gap between clinical trial promises and real-world outcomes for drugs like Ozempic and Wegovy.
儘管有着有希望的結果，最近的一項研究揭示了臨床試驗承諾與藥物如Ozempic和Wegovy在現實世界中的效果之間存在差距。
- Boeing Workers' Union Says Decision To Cut Health Care For 33,000 Is 'Unnecessary And Cruel'
- 波音工會表示裁減3.3萬人醫療保健福利的決定"不必要且殘忍"
Image Via Shutterstock
圖片來自Shutterstock。
This story was generated using Benzinga Neuro and edited by Kaustubh Bagalkote
本報道使用Benzinga Neuro生成，並由Kaustubh Bagalkote
譯文內容由第三人軟體翻譯。